# PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

> **NCT02571725** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **New Mexico Cancer Research Alliance** · enrollment: 50 (estimated)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Neoplasms

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT02571725
- **Lead sponsor:** New Mexico Cancer Research Alliance
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-02-23
- **Primary completion:** 2020-12-02
- **Final completion:** 2027-07-15
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02571725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02571725, "PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02571725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*